Publications by authors named "B S Harrow"
Article Synopsis
- Tenosynovial giant cell tumour (TGCT) is a locally aggressive tumor with limited treatment options, leading this study to assess vimseltinib, a CSF1R inhibitor, in patients whose TGCT symptoms prevent surgery.
- The MOTION trial, a phase 3 randomized study, involved 123 adults from 35 hospitals globally, comparing vimseltinib to a placebo over 24 weeks, focusing on the objective response rate determined by independent radiological review.
- Results showed a significant objective response rate of 40% for vimseltinib compared to 0% for placebo, with most side effects being mild (grade 1 or 2), highlighting vimseltinib's
Background And Objective: The tyrosine kinase inhibitors cabozantinib and axitinib have been widely used in England to treat advanced renal cell carcinoma following prior vascular endothelial growth factor-targeted therapy, but data on real-world usage remain limited. Our objective was to describe the real-world treatment patterns and outcomes of patients with advanced renal cell carcinoma who received second-line or later-line (≥ 2L) cabozantinib or axitinib after vascular endothelial growth factor-targeted therapy in clinical practice in England.
Methods: This retrospective cohort study used clinical practice data (collected 2011-20) from the English Cancer Analysis System database.
Purpose: In the INTRIGUE trial, ripretinib showed no significant difference versus sunitinib in progression-free survival for patients with advanced gastrointestinal stromal tumour (GIST) previously treated with imatinib. We compared the impact of these treatments on health-related quality of life (HRQoL).
Patients And Methods: Patients were randomised 1:1 to once-daily ripretinib 150 mg or once-daily sunitinib 50 mg (4 weeks on/2 weeks off).